Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation

Chronic Obstructive Pulmonary Disease-I: Introduction

Chronic Obstructive Pulmonary Disease-I: Introduction

Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...

COPD: Pathogenesis and Clinical Features

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...

Cardiomyopathy II: Dilated Cardiomyopathy

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...

Pulmonary Embolism I: Introduction

Pulmonary Embolism I: Introduction

Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Relationship between cognitive failures, sleepiness and road traffic incidents in patients with untreated obstructive sleep apnoea and controls.

ERJ open research·2026

Same author

Impact on clinical outcomes, surgical interventions, anaesthetic decisions and complication rates following implementation of the NICE obstructive sleep apnoea guidelines during preoperative screening.

Clinical medicine (London, England)·2024

Same author

An exploratory study evaluating the use of coping strategies while driving in obstructive sleep apnoea syndrome patients and controls.

ERJ open research·2024

Same author

The clinical course of pneumomediastinum in patients with SARS-CoV-2 before invasive mechanical ventilation.

Clinical medicine (London, England)·2022

Same author

Pneumomediastinum in a cannabis smoker precipitated by vigorous sexual intercourse.

BMJ case reports·2021

Same author

Colour of blood matters: a novel aetiology for a common addiction.

Internal medicine journal·2021

Search research articles

Related Experiment Video

Updated: Nov 8, 2025

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation

Published on: February 28, 2012

Amiodarone lung: under recognised but not forgotten.

Emma Baron¹, Wai Kit Mok¹, Manika Jayawardena¹

¹Mid Yorkshire Hospitals NHS Trust, Wakefield, UK.

The Journal of the Royal College of Physicians of Edinburgh

|April 20, 2021

Summary

Amiodarone-induced pulmonary toxicity (AIPT) can be fatal, even at low doses. This case highlights the need for vigilant monitoring of amiodarone lung complications to prevent severe outcomes.

Keywords:

clinical vigilance foamy macrophages pneumonitis pneumotoxic

More Related Videos

Implantation of Total Artificial Heart in Congenital Heart Disease

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

Related Experiment Videos

Last Updated: Nov 8, 2025

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation

Published on: February 28, 2012

Implantation of Total Artificial Heart in Congenital Heart Disease

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

Area of Science:

Cardiology
Pulmonology
Pharmacology

Background:

Amiodarone is a widely used antiarrhythmic medication.
It is associated with significant pulmonary and extrapulmonary adverse effects.
Amiodarone-induced pulmonary toxicity (AIPT), or amiodarone lung, is a serious complication.

Observation:

A case of amiodarone lung presented as acute fulminant pneumonitis.
The patient was on a low dose of amiodarone (100 mg daily).
The condition proved fatal, with diagnosis confirmed postmortem due to diagnostic challenges.

Findings:

Amiodarone lung can manifest with diverse clinical presentations, mimicking other conditions.
Fatal outcomes are possible even with low-dose amiodarone therapy.
Diagnosis can be challenging, sometimes requiring postmortem examination.

Implications:

Clinicians must regularly monitor patients for amiodarone adverse effects.
The necessity of long-term amiodarone use should be periodically reviewed.
Early detection and intervention are crucial for managing AIPT and preventing fatal complications.